8-K: Scholar Rock Reports Positive Q1 2025 Results, Awaits Apitegromab FDA Decision

Scholar Rock announced its Q1 2025 financial results and highlighted key business progress, including the FDA's priority review of apitegromab for SMA and advancements in commercial readiness.

Summary

• Scholar Rock reported its financial results and business updates for the first quarter ended March 31, 2025.
• The FDA granted priority review for the Biologics License Application (BLA) of apitegromab for Spinal Muscular Atrophy (SMA), with a PDUFA date set for September 22, 2025.
• The European Medicines Agency (EMA) validated the Marketing Authorisation Application (MAA) for apitegromab for SMA patients.
• Topline results from the Phase 2 EMBRAZE proof-of-concept trial in adult patients with obesity are expected in June 2025.
• The company's cash, cash equivalents, and marketable securities totaled $364.4 million as of March 31, 2025, expected to fund programs into 2027.
• The company expects to initiate the Phase 2 OPAL clinical trial in SMA in Q3 2025.
• An IND application for SRK-439 to support the first in human study remains on track and is expected to be filed in Q3 2025.
• Net loss for the quarter ended March 31, 2025, was $74.7 million, or $0.67 per share, compared to a net loss of $56.9 million, or $0.59 per share, for the quarter ended March 31, 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the FDA priority review, EMA validation, and strong cash position, but tempered by the increased net loss.

Positives

• Apitegromab received priority review from the FDA, potentially accelerating its approval for SMA.
• The EMA validated the MAA for apitegromab, paving the way for a potential European launch.
• Scholar Rock has a strong cash position of $364.4 million, providing financial stability into 2027.
• The company is progressing with commercial launch readiness for apitegromab in the U.S.
• Preclinical data supports the potential of apitegromab in Duchenne Muscular Dystrophy (DMD).

Negatives

• The company reported a net loss of $74.7 million for the quarter ended March 31, 2025, which is higher than the $56.9 million loss reported for the same period in 2024.
• The company did not record any revenue for the quarter ended March 31, 2025 or for the quarter ended March 31, 2024.

Risks

• The success of apitegromab is contingent on receiving regulatory approvals from the FDA and EMA.
• Clinical trial data may not be predictive of future results.
• The company faces competition from other companies developing products for similar uses.
• Scholar Rock depends on third parties for the development and manufacture of product candidates.

Future Outlook

Scholar Rock anticipates a potential U.S. commercial launch of apitegromab in Q3 2025, a European launch in 2026, and expects its cash to fund operations into 2027. The company also plans to initiate a Phase 2 trial in SMA and file an IND for SRK-439 in Q3 2025.

Management Comments

• Scholar Rock is at an inflection point as we evolve to a commercial-stage biopharmaceutical company, and our team remains focused on key priorities in preparation for the potential U.S. launch of apitegromab in Q3 2025, said David L. Hallal, Chief Executive Officer of Scholar Rock.
• With the FDA granting our BLA priority review and review of the MAA underway in Europe, I am delighted we have bolstered our leadership with the appointments of Akshay Vaishnaw, Keith Woods and Vikas Sinha as we scale our operations to serve patients with SMA in the U.S., Europe and in many additional countries around the world.

Industry Context

Scholar Rock is positioning itself to be a leader in neuromuscular disease, particularly in SMA, where there is a significant unmet need despite the availability of SMN-targeted therapies. The company is also exploring the potential of apitegromab in other neuromuscular disorders and cardiometabolic conditions.

Comparison to Industry Standards

• Apitegromab is positioned as a potential first-in-class, best-in-class SMA therapy, targeting muscle degeneration, a critical unmet need despite existing SMN-targeted therapies like Spinraza (Biogen), Evrysdi (Roche), and Zolgensma (Novartis).
• The Phase 3 SAPPHIRE trial results, showing statistically significant motor function improvement, are compared against the Hammersmith Functional Motor Scale Expanded (HFMSE), a gold standard in SMA clinical trials.
• The company's approach of combining SMN-dependent and SMN-independent treatments aligns with the evolving understanding that multiple modalities are necessary to treat SMA effectively, as supported by research from Cure SMA and neurologist opinions.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased value upon successful commercialization of apitegromab.
• Patients with SMA: Potential access to a new treatment option that addresses muscle degeneration.
• Employees: Opportunity to work on a potentially groundbreaking therapy and contribute to the company's growth.
• Customers: Access to a new therapy that could improve their quality of life.
• Suppliers: Potential for increased business as the company scales up its operations.

Next Steps

• Await FDA decision on apitegromab BLA by September 22, 2025.
• Advance U.S. commercial launch readiness for apitegromab.
• Progress launch preparedness in Germany and other European markets.
• Initiate Phase 2 OPAL clinical trial in SMA in Q3 2025.
• File IND application for SRK-439 in Q3 2025.
• Report topline data from Phase 2 EMBRAZE trial in obesity in June 2025.

Key Dates

Keywords

apitegromab, SMA, Spinal Muscular Atrophy, Scholar Rock, BLA, MAA, PDUFA, clinical trial, SRK-439, neuromuscular disorders, FDA, EMA, commercial launch, financial results